Today, only 8% of central nervous system (CNS) drugs starting in clinical development are approved, suggesting a low predictiveness of preclinical animal models and other early drug targeting and testing methods.
The first part of In Silico Biosciences’ mission is to build mechanistic mathematical models of large scale CNS disease physiologies. This is based upon the integration of current knowledge so as to better understand the pathological processes in the human brain vs. an animal brain. A multiplicity of validation methodologies are utilized for the models. The goal is to support the drug discovery processes and to help develop better drugs, especially CNS drugs which deliberately affect multiple targets.
The second part of our mission is to discover and do early stage development of multi-target CNS compounds. Based on insights gained through the company’s physiology modeling programs, the company has determined the minimum combination of targets that most powerfully affects the outcome of schizophrenia. The platform is optimally suited to drive such a multi-targeting drug discovery project.
Click here to enter website (password required).
E-mail info2@in-silico-biosciences.com for information and access.